Zobrazeno 1 - 10
of 42
pro vyhledávání: '"S J Ryan Arends"'
Autor:
Rodrigo E. Mendes, S. J. Ryan Arends, Jennifer M. Streit, Ian Critchley, Nicole Cotroneo, Mariana Castanheira
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 1 (2023)
ABSTRACT Tebipenem pivoxil is an oral broad-spectrum carbapenem. This study evaluated the activity of tebipenem and comparators against UTI Enterobacterales from US hospitals (2019–2020). 3,576 Enterobacterales causing UTI in 52 centers in 9 US Cen
Externí odkaz:
https://doaj.org/article/173addc9937b4bc3a445f4b1e613e521
Autor:
Lucero Martínez-Fructuoso, S. J. Ryan Arends, Vitor F. Freire, Jason R. Evans, Sean DeVries, Brian D. Peyser, Rhone K. Akee, Christopher C. Thornburg, Rohitesh Kumar, Susan Ensel, Gina M. Morgan, Grant D. McConachie, Nathan Veeder, Leonard R. Duncan, Tanja Grkovic, Barry R. O’Keefe
Publikováno v:
ACS Infectious Diseases.
Autor:
S. J. Ryan Arends, Deborah Butler, Nicole Scangarella-Oman, Mariana Castanheira, Rodrigo E. Mendes
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
The in vitro activities of gepotidacin and comparator agents against 3,560 Escherichia coli and 344 Staphylococcus saprophyticus collected from female (81.1%) and male (18.9%) patients with urinary tract infections (UTIs) in a global prospective surv
Autor:
Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Cecilia G. Carvalhaes, Mariana Castanheira
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 41:477-487
Autor:
Rodrigo E Mendes, S J Ryan Arends, John H Kimbrough, Valerie Kantro, Deborah Butler, Nicole E Scangarella-Oman, Jennifer M Streit, Mariana Castanheira
Publikováno v:
Open Forum Infectious Diseases. 9
Background Gepotidacin is a novel first in class triazaacenaphthylene antibiotic in Phase 3 clinical trials for the treatment of gonorrhea and uncomplicated urinary tract infection (UTI). This study evaluates the epidemiology of E. coli (EC) causing
Publikováno v:
Open Forum Infectious Diseases. 9
Background Lefamulin is a novel pleuromutilin protein synthesis inhibitor approved in the US, Canada, and Europe for the oral and intravenous treatment of community-acquired bacterial pneumonia (CABP) in adults due to typical and atypical pathogens.
Autor:
Rodrigo E Mendes, Helio S Sader, S J Ryan Arends, Nicole Cotroneo, Ian A Critchley, Mariana Castanheira
Publikováno v:
Open Forum Infectious Diseases. 9
Background SPR206 is a next generation polymyxin being developed to treat serious infections caused by Gram-negative (GN) multidrug-resistant (MDR) pathogens. The in vitro activity of SPR206 and comparators were monitored against GN pathogens causing
Publikováno v:
Open Forum Infectious Diseases. 9
Background P. aeruginosa (PSA) is one of the most common Gram-negative organisms causing infections in hospitalized patients. Prompt administration of an effective antimicrobial is crucial for patients with systemic PSA infection. We evaluated the in
Autor:
Mariana Castanheira, S. J. Ryan Arends, Andrew P. Davis, Leah N. Woosley, Amira A. Bhalodi, Shawn H. MacVane
Publikováno v:
mSphere, Vol 3, Iss 5 (2018)
ABSTRACT A blaKPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. The initial and follow-up isolates exhibited ceftazidime-avibactam MICs of 4 and 64 µg/ml, respectively. Overexpre
Externí odkaz:
https://doaj.org/article/03baac5888cf4fe3a5024e729a3b03a1
Autor:
Helio S, Sader, Mariana, Castanheira, Cecilia G, Carvalhaes, S J Ryan, Arends, Rodrigo E, Mendes
Publikováno v:
Microbial drug resistance (Larchmont, N.Y.). 28(9)
We evaluated the activity of ceftaroline against clinical isolates of ceftriaxone-nonsusceptible